Pain, Pancreatic Cancer
Conditions
Keywords
recurrent pancreatic cancer, stage III pancreatic cancer, stage IV pancreatic cancer, adenocarcinoma of the pancreas, pain, stage II pancreatic cancer
Brief summary
RATIONALE: Giving medications in different ways may change their effectiveness in controlling pain. It is not yet known whether intrathecal therapy is more effective than standard therapy in controlling pain in patients with pancreatic cancer. PURPOSE: This randomized clinical trial is studying standard pain control to see how well it works compared with intrathecal therapy in controlling pain in patients with locally advanced, unresectable, or metastatic pancreatic cancer.
Detailed description
OBJECTIVES: Primary * To compare the effectiveness of pain control comprising intrathecal opioid delivery versus the standard analgesia-delivery method in patients with locally advanced, unresectable, or metastatic pancreatic cancer. Secondary * To assess the difference of a total amount of opioid consumption (parenteral morphine equivalent) between two different opioids-delivery groups at one month of treatment. * To assess the average of percent change in Karnofsky performance status with respect to the baseline status between two different analgesic-delivery groups at one month of treatment. * To assess the difference in quality of life between two different opioids-delivery groups at one month of treatment using the EORTC QLQ-C30. * To assess overall survival of these patients. * To assess the safety profile of two different analgesic-delivery methods (i.e., adverse event and serious adverse event). OUTLINE: Patients are stratified according to Karnofsky performance status (60-80% vs \> 80%). Patients are randomized to 1 of 2 treatment arms. * Arm I (standard pain management): Patients are evaluated by the JHH Pain Medicine Integrated Team for pain, for the potential of diagnostic/neurolytic celiac plexus block, and undergo the institution of or modification of or continuation and titration of oral or parenteral analgesics. Patients undergo a limited, problem-oriented physical exam including weight, vital signs, Karnofsky performance status (KPS), assessment of previously abnormal findings or new complaints, pain scores, analgesia consumption, side effects (i.e., sleepiness, nausea, pruritus, and constipation), and quality-of-life score (EORTC QLQ-C30) once every 2 weeks for 3 months and then once a month thereafter. Patients also keep a diary of pain scores and side effects during the trial. Patients may have their treatment titrated as needed to control their pain. Patients who are not adequately pain controlled or develop debilitating side effects from their therapy may be managed by adjuvant analgesics or be allowed to crossover into the treatment arm of the study to provide compassionate care. * Arm II (intrathecal therapy): Patients undergo implantation of a Medtronic intrathecal pump and catheter system for delivery of morphine sulfate directly into the spinal fluid. Following implantation, patients undergo a limited, problem-oriented physical exam including vital signs, KPS, assessment of previously abnormal findings or new complaints, pain scores, analgesia consumption, and quality-of life-score (EORTC QLQ-C30) once every 2 weeks for 3 months and then once a month thereafter. Patients are also evaluated by the Interventional Pain Treatment Team for wound status, presence of symptoms of post-dural puncture headache, signs of infection, or meningitis. Patients are followed by the JHH Pain Medicine Integrated Team for evaluation of pain and for institution of or modification of or continuation and titration of oral or parenteral analgesics. After completion of study treatment, patients are followed for 1 year.
Interventions
DRUGmorphine sulfate
This is morphine given in the traditional methods.
DEVICEMedtronic intrathecal pump
This pump will be inserted into the research subject and then the pump will deliver morphine.
Sponsors
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: Inclusion criteria: * Histologically confirmed adenocarcinoma of the pancreas * Mixed adenocarcinoma tumors allowed provided the predominant invasive component of the tumor is adenocarcinoma * Locally advanced, unresectable, or metastatic disease * Patients must be within two months of diagnosis or have started chemotherapy within 60 days of study * Average pain score ≥ 4/10 over a 7-day period on a verbal numerical rating scale
Exclusion criteria
* Known brain metastases * Tumor with clinically significant obstruction of the spinal canal PATIENT CHARACTERISTICS: Inclusion criteria: * Karnofsky performance status 60-100% * ANC ≥ 1,500 cells/mm³ * Hematocrit ≥ 28% * WBC ≥ 3,500 cells/mm³ * Platelets ≥ 90,000/mm³ * Serum creatinine ≤ 2.0 mg/dL * Bilirubin ≤ 2.5 mg/dL * AST/ALT ≤ 5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 5 times ULN * INR ≤ 1.5 * Not pregnant or nursing * Negative pregnancy test * Mini-mental status exam score ≥ 22
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Per Arm With Decrease in Pain Scores | 1 month | The primary objective of this study is to compare the effectiveness of pain control between intrathecal opioid delivery and standard analgesia delivery method in patients with locally advanced unresectable or metastatic pancreatic cancer. The primary end point is the number of subjects on each arm showing a decrease in the change in VAS self-assessment pain intensity rating (VAS pain rating) at one month from initial treatment with respect to the baseline pain score. The change is defined as (the Pain Score at one month of the treatment - the Pain Score at baseline). Serial pain scores will be collected at all assessment time points. Min: zero cm. Max 10cm. A higher value means worse pain. Subjects on each arm will report pain on a 10 cm Visual Analogue Scale (VAS) pain rating scale, by making a mark on the 10cm horizontal line with a pen and study team will measure distance from the mark to the start of the scale, which will indicate pain score (eg 1 cm, 3 cm 6 cm, etc.). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Morphine morphine given traditionally (IV, pill, patch)
morphine sulfate: This is morphine given in the traditional methods. | 1 |
| Intrathecal Pump Pump internal used to deliver morphine. This is a newer method for delivery of morphine.
Medtronic intrathecal pump: This pump will be inserted into the research subject and then the pump will deliver morphine. | 0 |
| Total | 1 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Morphine | Total |
|---|---|---|
| Age, Categorical <=18 years | 0 participants | 0 participants |
| Age, Categorical >=65 years | 0 participants | 0 participants |
| Age, Categorical Between 18 and 65 years | 1 participants | 1 participants |
| Age, Continuous | 55 years | 55 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 participants | 0 participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 participants | 1 participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 participants | 0 participants |
| Gender Female | 1 participants | 1 participants |
| Gender Male | 0 participants | 0 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 participants | 0 participants |
| Race (NIH/OMB) Asian | 0 participants | 0 participants |
| Race (NIH/OMB) Black or African American | 0 participants | 0 participants |
| Race (NIH/OMB) More than one race | 0 participants | 0 participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 participants | 0 participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 participants | 0 participants |
| Race (NIH/OMB) White | 1 participants | 1 participants |
| Region of Enrollment United States | 1 participants | 1 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 1 / 1 | 0 / 0 |
| serious Total, serious adverse events | 1 / 1 | 0 / 0 |
Outcome results
Primary
Number of Subjects Per Arm With Decrease in Pain Scores
The primary objective of this study is to compare the effectiveness of pain control between intrathecal opioid delivery and standard analgesia delivery method in patients with locally advanced unresectable or metastatic pancreatic cancer. The primary end point is the number of subjects on each arm showing a decrease in the change in VAS self-assessment pain intensity rating (VAS pain rating) at one month from initial treatment with respect to the baseline pain score. The change is defined as (the Pain Score at one month of the treatment - the Pain Score at baseline). Serial pain scores will be collected at all assessment time points. Min: zero cm. Max 10cm. A higher value means worse pain. Subjects on each arm will report pain on a 10 cm Visual Analogue Scale (VAS) pain rating scale, by making a mark on the 10cm horizontal line with a pen and study team will measure distance from the mark to the start of the scale, which will indicate pain score (eg 1 cm, 3 cm 6 cm, etc.).
Time frame: 1 month
Population: One subject was enrolled, and baseline pain score was obtained on questionnaire, but the subject came off-study before follow-up pain score could be collected. Study terminated shortly thereafter. No outcome data were collected.